Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLO1 | Q04760 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3400931 | 0.81 | EP300 (0.43) | GLO1ALDH1A1TSHRNPSR1 | |
| SCHEMBL11771656 | 0.77 | ALDH1A1 (0.33) | GLO1ALDH1A1TSHRTHRBNPSR1 | |
| SCHEMBL2173521 | 0.77 | NPSR1 (0.52) | GLO1ALDH1A1TSHRLMNAHSD17B10 | |
| SCHEMBL211093 | 0.74 | ALDH1A1 (0.37) | GLO1ALDH1A1TSHRLMNAHSD17B10 | |
| SCHEMBL294026 | 0.74 | — | — | |
| SCHEMBL2829659 | 0.73 | ALOX15 (0.36) | ALDH1A1TSHRLMNAHSD17B10THRB | |
| SCHEMBL22607728 | 0.73 | NPSR1 (0.47) | GLO1ALDH1A1TSHRLMNAHSD17B10 | |
| SCHEMBL11730263 | 0.71 | — | — | |
| SCHEMBL11731268 | 0.71 | — | — | |
| SCHEMBL20782425 | 0.71 | NPSR1 (0.46) | GLO1ALDH1A1TSHRLMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298889-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING 2-PYRIDONE DERIVATIVES AS EFFECTIVE COMPONENTS | SATO PHARMACEUTICAL CO., LTD. (JP) | 2009-12-03 | — | — | US | disclosed |
| EP-1897870-A1 | PHARMACEUTICAL COMPOSITION COMPRISING 2-PYRIDONE DERIVATIVE AS ACTIVE INGREDIENT | Sato Pharmaceutical Co. Ltd. (JP) | 2008-03-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298889-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING 2-PYRIDONE DERIVATIVES AS EFFECTIVE COMPONENTS | LTB4R2, LTB4R, CD4 | GLO1 2438/4885ALDH1A1 436/4885TSHR 2896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.